Astragalus Extract
The root of the astragalus plant contains rare compounds that directly protect chromosomes from the wear and tear of biological aging. Its primary active molecule, cycloastragenol, activates the telomerase enzyme to shield DNA ends from degradation during cellular division. Beyond this fundamental cellular protection, the extract serves as a potent immunomodulator that stimulates natural killer cells and enhances immune cell proliferation. In clinical applications, supplementation over 8 to 12 weeks has been shown to improve vaccine responses and reduce upper respiratory infection rates in healthy adults. When used as an adjunct to platinum-based chemotherapy, it has demonstrated a 33 percent improvement in one-year survival odds by countering treatment-induced immunosuppression. By operating at the intersection of innate immunity and cellular senescence, astragalus extract offers a powerful botanical strategy for extending healthspan and preserving systemic resilience.
Key Takeaways
- •Astragaloside IV and its aglycone cycloastragenol are the primary bioactives responsible for astragalus extract's telomerase-activating properties. These triterpenoid saponins upregulate hTERT (human telomerase reverse transcriptase) gene expression, the catalytic subunit that is the rate-limiting component of telomerase activity in most somatic cells. Clinical studies (Harley et al., 2011) found that cycloastragenol supplementation increased the percentage of long telomeres in immune cell populations, suggesting functional telomere maintenance activity.
- •POT1 (protection of telomeres 1) is a key component of the shelterin complex that caps chromosome ends and regulates access of telomerase to the telomere substrate. Telomerase activation by cycloastragenol works within the context of the existing shelterin complex: POT1 normally prevents unregulated telomerase access, but when telomeres become critically short, POT1 conformation changes to permit telomerase elongation. Astragalus-derived compounds are proposed to shift this equilibrium toward permissive telomerase engagement while POT1 maintains structural telomere protection.
- •A placebo-controlled trial by Harley et al. (2011, Rejuvenation Research, n=117) found that cycloastragenol supplementation significantly increased the proportion of short telomeres in CD4+ and CD8+ T-lymphocytes over one year of treatment, with a corresponding shift in immune function markers toward younger immune cell profiles. This was the first published RCT evidence of telomerase activation by a dietary supplement in humans.
- •Astragalus polysaccharides (APS) represent a distinct class of bioactives from the saponins, with potent immunomodulatory effects. APS activate macrophages, dendritic cells, and natural killer cells through toll-like receptor 4 (TLR4) signaling. Clinical studies in cancer patients receiving chemotherapy have shown that APS supplementation reduces chemotherapy-induced immunosuppression, reduces infection rates, and improves patient-reported quality of life scores.
- •As a classical TCM adaptogen, astragalus modulates the hypothalamic-pituitary-adrenal (HPA) axis. In stress models, astragalus extract reduces cortisol elevation and normalizes HPA reactivity, positioning it as an adaptogen that buffers excessive stress responses without suppressing basal cortisol. This property distinguishes it from stimulant-type energy enhancers and supports its traditional use as a fatigue-reducing tonic.
- •Astragalus extract has demonstrated immunomodulatory effects in multiple clinical trials in cancer patients receiving platinum-based chemotherapy. A meta-analysis of 34 RCTs (n=2,815) found that astragalus-based treatments significantly improved one-year survival, tumor response rates, and quality of life in non-small cell lung cancer patients on chemotherapy, representing the most robust clinical evidence base for any therapeutic application of astragalus.
Basic Information
- Name
- Astragalus Extract
- Also Known As
- Astragalus membranaceusHuang Qimilk vetch rootastragaloside IVcycloastragenolTA-65astragalus polysaccharides (APS)membranous milkvetch
- Category
- Adaptogenic root herb (triterpenoid saponins + polysaccharides)
- Bioavailability
- Astragaloside IV is a large triterpenoid saponin glycoside with very low oral bioavailability in intact form, estimated at below 1 percent due to its high molecular weight (784 Da) and poor intestinal permeability. Gut bacteria partially deglycosylate astragaloside IV to cycloastragenol (the aglycone), which has somewhat better absorption. Cycloastragenol formulated as TA-65 (a patented extract) shows measurable plasma levels after oral supplementation. Astragalus polysaccharides (APS) are absorbed by endocytosis in intestinal epithelial cells and show better bioavailability than the saponins. Lipid-based delivery systems and nanoparticle formulations significantly improve astragaloside IV absorption in preclinical studies.
- Half-Life
- Cycloastragenol has a plasma half-life of approximately 4 to 8 hours in rodent studies, with tissue concentrations in immune-relevant tissues (spleen, lymph nodes, thymus) significantly exceeding plasma levels. Human pharmacokinetic data for astragaloside IV are limited. Standard supplementation protocols typically use twice-daily dosing to maintain biological effect. The telomere-related effects are cumulative over weeks to months rather than acute, suggesting tissue accumulation or downstream transcriptional effects with longer kinetics than plasma drug levels.
Primary Mechanisms
hTERT gene upregulation: astragaloside IV and cycloastragenol increase transcription of the telomerase catalytic subunit, activating telomerase in normally telomerase-silent somatic cells
Telomerase substrate access modulation: interaction with the POT1/shelterin complex to shift the balance toward permissive telomerase engagement at critically short telomeres
TLR4 activation by astragalus polysaccharides (APS), stimulating macrophage, dendritic cell, and NK cell innate immune activation
HPA axis modulation: normalization of cortisol stress responses, buffering excessive HPA reactivity without suppressing basal function
Nrf2/ARE pathway activation increasing antioxidant enzyme expression (SOD, catalase, GPx, HO-1)
NF-kappaB suppression reducing pro-inflammatory cytokine production
PI3K-AKT pathway activation contributing to cardioprotective and anti-apoptotic effects
AMPK activation supporting energy metabolism and cellular stress resistance
Quick Safety Summary
For general immune and adaptogenic use, standardized astragalus root extract is typically used at 400 to 1,200 mg per day (standardized to 70 percent polysaccharides or 0.5 percent astragaloside IV). For the telomere-targeting cycloastragenol/TA-65 product, doses of 5 to 100 mg per day have been used in studies. Injectable astragaloside IV (used in some Asian clinical trials) is not available as a dietary supplement. Most safety data come from 8 to 24 week trials; long-term safety beyond 2 years is not established.
Autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis): astragalus immunostimulatory activity may exacerbate autoimmune conditions; avoid or use only under specialist supervision, Organ transplantation (immunosuppression): astragalus immune stimulation may antagonize immunosuppressive medications required for organ rejection prevention; contraindicated post-transplant, Pregnancy and breastfeeding: traditional use includes pregnancy tonics in some TCM traditions, but safety data for standardized high-dose extracts are insufficient for modern recommendation; avoid high-dose supplementation, Thyroid disorders: astragalus has been reported to modulate thyroid hormone levels in some studies; monitoring is appropriate in patients with thyroid disease, Active acute infections with fever: while astragalus is used for immune support, traditional TCM cautions against use during acute febrile infections, preferring it as a prophylactic and recovery tonic
Overview
Astragalus membranaceus is a perennial herb native to northeastern China and Mongolia, where it has been used in Traditional Chinese Medicine for over 2,000 years as Huang Qi (yellow leader), one of the most important tonic herbs in the Chinese pharmacopoeia. The dried root contains hundreds of bioactive compounds, most importantly two distinct classes: triterpenoid saponins (including astragalosides I through IV, with astragaloside IV and its aglycone cycloastragenol being the most bioactive) and polysaccharides (astragalus polysaccharides or APS, particularly APS1, APS2, and APS3). These two compound classes have complementary but distinct mechanisms: the saponins are responsible for the telomerase-activating and adaptogenic properties, while the polysaccharides drive the immunostimulatory and anti-inflammatory effects. Modern astragalus supplements are typically standardized to one or both of these compound classes.
The discovery that astragaloside IV and cycloastragenol activate telomerase placed astragalus at the center of longevity biology research. Telomerase is a ribonucleoprotein complex that adds TTAGGG repeats to the 3' ends of chromosomes (telomeres), counteracting the progressive telomere shortening that occurs with each cell division due to the end-replication problem. In most somatic cells, telomerase expression is silenced at the hTERT (human telomerase reverse transcriptase) gene promoter, limiting the lifespan of dividing cell populations. As cells approach critically short telomeres, they undergo replicative senescence or apoptosis, contributing to tissue aging and immune decline. Cycloastragenol upregulates hTERT transcription through mechanisms involving Sp1 transcription factor binding and histone acetylation changes at the hTERT promoter. This activation is not unlimited; it preferentially activates telomerase in cells with shorter telomeres, suggesting a length-sensing mechanism that prevents catastrophic telomere lengthening while selectively extending the replicative capacity of cells approaching senescence.
The shelterin complex, a six-protein structure at chromosome ends (TRF1, TRF2, RAP1, TIN2, TPP1, and POT1), both protects telomeres and regulates telomerase access. POT1 (protection of telomeres 1) binds the single-stranded 3' telomere overhang and is the primary gatekeeper of telomerase engagement. When telomeres are long, POT1 adopts a conformation that prevents telomerase from accessing the telomere end. When telomeres become critically short, the shelterin complex changes conformation, POT1 releases the telomere overhang, and telomerase can extend it. Cycloastragenol and astragaloside IV are proposed to modulate this conformational equilibrium, lowering the threshold telomere length at which POT1 releases the overhang and permits telomerase elongation, effectively increasing the efficiency of telomere maintenance without disrupting the fundamental protection function of POT1 and shelterin.
Beyond its telomere biology, astragalus has robust clinical evidence in immunomodulation and cancer treatment support contexts. The astragalus polysaccharide fraction activates innate immunity through TLR4 (toll-like receptor 4) signaling on macrophages and dendritic cells, inducing phagocytosis, cytokine production, and antigen presentation. This immunostimulation is distinct from the saponin telomerase mechanism and has been extensively studied in the context of chemotherapy support in Chinese clinical medicine. Standard oral supplements range from 400 to 1,200 mg of standardized extract per day for general immune and adaptogenic purposes; the telomerase-targeted cycloastragenol product (TA-65) uses much smaller doses (5 to 100 mg per day) of the purified aglycone.
Core Health Impacts
- • Telomere maintenance and cellular aging: Astragaloside IV and cycloastragenol activate telomerase by upregulating hTERT expression, potentially slowing telomere erosion in dividing cells. The Harley et al. 2011 RCT (n=117) showed a significant reduction in the proportion of short telomeres in T-lymphocytes after one year of cycloastragenol supplementation, with a shift toward longer telomere distributions. Short telomeres drive replicative senescence and impair immune cell longevity; maintaining telomere length in immune cells is associated with preserved immune function in aging. These findings are preliminary but represent the most direct human evidence for dietary telomerase activation.
- • Immune function enhancement: Astragalus polysaccharides (APS) are potent immunomodulators that activate TLR4 on macrophages and dendritic cells, stimulate natural killer cell cytotoxicity, and enhance T-lymphocyte proliferation and Th1 cytokine production. Multiple RCTs in healthy adults have demonstrated improved vaccine immune response, higher NK cell counts, and reduced upper respiratory infection rates with astragalus supplementation over 8 to 12 weeks. These immunostimulatory effects are distinct from the telomerase mechanism and operate independently through innate and adaptive immune activation.
- • Cancer treatment support: The most clinically robust application of astragalus is as an adjunct to chemotherapy. A Cochrane-level meta-analysis of 34 RCTs (n=2,815) in NSCLC patients found that astragalus-based Chinese medicine formulations combined with platinum-based chemotherapy significantly improved one-year survival odds by 33 percent, tumor response rates by 35 percent, and reduced chemotherapy toxicity scores. While these trials used combined formulas, astragalus was a consistent component. The proposed mechanisms include immune preservation (countering chemotherapy-induced immunosuppression) and anti-tumor synergy through macrophage and NK cell activation.
- • Adaptogenic fatigue reduction: Astragalus is classified as an adaptogen in both TCM and modern phytomedicine frameworks, meaning it helps the body resist physical and psychological stressors without stimulation. Clinical evidence for fatigue reduction includes a 2017 RCT in patients with chronic fatigue syndrome (n=74) showing significant reductions in fatigue scores compared to placebo after 8 weeks of astragalus supplementation. The mechanism involves HPA axis modulation, mitochondrial energy pathway support, and antioxidant reduction of oxidative stress-driven fatigue.
- • Cardiovascular protection: Astragaloside IV demonstrates direct cardioprotective effects in animal models of myocardial infarction and heart failure, reducing infarct size, improving left ventricular function, and inhibiting cardiomyocyte apoptosis through PI3K-AKT and Nrf2 pathway activation. In human studies, a 2013 randomized trial found astragaloside IV injection improved left ventricular ejection fraction and reduced plasma BNP in heart failure patients, though injectable forms are separate from oral dietary supplements.
- • Antioxidant and anti-inflammatory effects: Astragalus extract increases superoxide dismutase (SOD) and catalase activity in clinical trials, with significant reductions in malondialdehyde (a lipid peroxidation marker). The anti-inflammatory mechanism involves NF-kappaB pathway suppression, reduced macrophage TNF-alpha and IL-1beta production, and AMPK activation. These antioxidant and anti-inflammatory effects complement the telomere-protective and immunostimulatory properties and contribute to the overall anti-aging and vitality-enhancing effects reported in clinical use.
- • Kidney protection: Multiple clinical trials in patients with diabetic nephropathy, IgA nephropathy, and chronic kidney disease have demonstrated that astragalus-based treatments significantly reduce urinary protein excretion, improve GFR preservation, and reduce inflammatory markers in renal tissue. The proposed mechanisms include TGF-beta inhibition (anti-fibrotic), reduction of glomerular inflammation, and antioxidant protection of tubular cells. A 2014 meta-analysis of 20 RCTs found significant reductions in 24-hour urinary protein excretion in diabetic nephropathy patients.
- • Antiviral immune support: Astragalus has documented antiviral activity in multiple virus models, including influenza, hepatitis C, herpes simplex, and coxsackievirus B3. The mechanism involves interferon alpha induction, natural killer cell activation, and direct inhibition of viral replication in some models. Clinical trials in patients with chronic hepatitis C have shown astragalus supplementation improves liver function markers and immune parameters. Traditional use as a respiratory infection preventative is supported by the TLR4-mediated innate immune activation mechanism.
Gene Interactions
Key Gene Targets
POT1
Astragalus-derived cycloastragenol and astragaloside IV activate telomerase by upregulating hTERT expression and are proposed to work in coordination with POT1 (protection of telomeres 1), the shelterin subunit that normally restricts telomerase access to chromosome ends. By shifting the conformational equilibrium of the POT1-shelterin complex toward permissive telomerase engagement at critically short telomeres, these compounds may selectively enhance telomere maintenance in cells most at risk of senescence without disrupting POT1's fundamental role in protecting telomere integrity from DNA damage responses.
Safety & Dosing
Contraindications
Autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis): astragalus immunostimulatory activity may exacerbate autoimmune conditions; avoid or use only under specialist supervision
Organ transplantation (immunosuppression): astragalus immune stimulation may antagonize immunosuppressive medications required for organ rejection prevention; contraindicated post-transplant
Pregnancy and breastfeeding: traditional use includes pregnancy tonics in some TCM traditions, but safety data for standardized high-dose extracts are insufficient for modern recommendation; avoid high-dose supplementation
Thyroid disorders: astragalus has been reported to modulate thyroid hormone levels in some studies; monitoring is appropriate in patients with thyroid disease
Active acute infections with fever: while astragalus is used for immune support, traditional TCM cautions against use during acute febrile infections, preferring it as a prophylactic and recovery tonic
Drug Interactions
Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids): astragalus immunostimulatory activity may directly antagonize immunosuppressive therapy; avoid combination
Anticoagulants (warfarin): some astragalus compounds may have mild anticoagulant activity; INR monitoring recommended if combining with warfarin therapy
Cyclophosphamide: astragalus polysaccharides have been shown to partially counteract cyclophosphamide-induced immunosuppression, which may be beneficial in cancer treatment contexts but unpredictable in immunological disease treatment
Hypoglycemic medications (metformin, insulin, sulfonylureas): astragalus has mild glucose-lowering activity; additive effects may increase hypoglycemia risk in diabetic patients on medications
Diuretics and antihypertensives: astragalus may have mild diuretic and blood pressure-modulating effects; monitor if combining with these drug classes
Lithium: astragalus may reduce renal lithium clearance through diuretic effects, potentially raising lithium levels; avoid combination
Common Side Effects
Generally well tolerated with mild GI symptoms (bloating, nausea, loose stools) in a small percentage of users
Mild skin rash or allergic reactions in individuals sensitive to Leguminosae (legume/bean) family plants, to which Astragalus belongs
Headache reported in a small percentage of users; typically transient and resolving within the first week of supplementation
Studied Doses
For general immune and adaptogenic use, standardized astragalus root extract is typically used at 400 to 1,200 mg per day (standardized to 70 percent polysaccharides or 0.5 percent astragaloside IV). For the telomere-targeting cycloastragenol/TA-65 product, doses of 5 to 100 mg per day have been used in studies. Injectable astragaloside IV (used in some Asian clinical trials) is not available as a dietary supplement. Most safety data come from 8 to 24 week trials; long-term safety beyond 2 years is not established.
Mechanism of Action
Telomerase Activation via hTERT Upregulation
The most scientifically distinctive mechanism of astragalus extract is its ability to activate telomerase in somatic cells, which normally have telomerase silenced. Telomerase is a ribonucleoprotein complex composed of two core components: hTERT (human telomerase reverse transcriptase), the catalytic subunit that adds TTAGGG repeats to telomere ends, and hTR (human telomerase RNA), the template RNA component. In most somatic cells, hTERT gene expression is epigenetically silenced through DNA methylation and histone deacetylation at the hTERT promoter. This silencing results in progressive telomere shortening with each cell division, eventually triggering replicative senescence when telomeres reach a critically short length.
Astragaloside IV and its aglycone cycloastragenol upregulate hTERT transcription through effects on Sp1 transcription factor binding to the hTERT promoter and through chromatin remodeling that increases promoter accessibility. The result is increased hTERT mRNA and protein levels, reconstitution of functional telomerase complex activity, and active telomere elongation. This activation appears to be preferentially engaged in cells with shorter telomeres, suggesting either a length-sensing mechanism or a threshold for the transcriptional response. Liu et al. (2017, Rejuvenation Research, PMID 28051904) confirmed dose-dependent increases in hTERT mRNA and functional telomerase activity in human T-lymphocytes treated with cycloastragenol, with specificity for hTERT over other telomerase components.
POT1 and Shelterin Complex Interaction
Telomerase activation is regulated not only at the level of hTERT expression but also at the level of substrate access: telomerase can only extend telomeres when it can access the single-stranded 3’ overhang at chromosome ends. The shelterin complex, a six-protein structure (TRF1, TRF2, RAP1, TIN2, TPP1, POT1), constitutively occupies telomere ends and physically restricts telomerase access. POT1 (protection of telomeres 1), the shelterin subunit that directly contacts the single-stranded telomere overhang, is the primary regulator of telomerase engagement. When telomeres are long, POT1 is stably bound and blocks telomerase access. When telomeres shorten to critical lengths, the changing geometry of the shelterin complex alters POT1 binding mode, releasing the overhang for telomerase extension.
Cycloastragenol and astragaloside IV are proposed to work within this regulatory framework by modulating the energetics of POT1 conformation transitions, effectively shifting the threshold length at which POT1 releases the telomere overhang for telomerase engagement. This positions the compound as a sensitizer of the telomere elongation machinery rather than an override of telomere protection, which is an important distinction from oncogenic telomerase activation that bypasses all control mechanisms. The shelterin complex, including POT1, continues to provide its protective function; the compounds simply lower the telomere length threshold at which extension occurs.
Immunomodulation via TLR4 and Innate Immunity
Astragalus polysaccharides (APS), the other major bioactive class, have a completely distinct mechanism from the saponins: they activate toll-like receptor 4 (TLR4) on macrophages, dendritic cells, and natural killer cells. TLR4 is the pattern recognition receptor that normally detects bacterial lipopolysaccharide (LPS); APS acts as a structural mimic of TLR4 ligands, triggering MyD88-dependent NF-kappaB signaling and TRIF-dependent IRF3 signaling in innate immune cells. The downstream effects include enhanced macrophage phagocytosis, increased macrophage-derived TNF-alpha and IL-12 (Th1-skewing cytokines), increased dendritic cell maturation and antigen presentation, and enhanced natural killer cell cytotoxicity. In the clinical context, this innate immune activation explains the preserved and enhanced immune function observed in cancer patients on chemotherapy who receive astragalus supplementation.
Adaptogenic HPA Axis Modulation
Astragalus is classified as an adaptogen because it normalizes rather than simply stimulates or suppresses physiological stress responses. In the context of the HPA (hypothalamic-pituitary-adrenal) axis, repeated stressor exposure causes progressive dysregulation of the cortisol stress response. Astragalus extract attenuates excessive cortisol elevation during acute stress in animal models, reduces corticotropin-releasing hormone (CRH) expression in the hypothalamus under chronic stress conditions, and appears to reset HPA axis sensitivity toward a healthier set point. Unlike stimulants or cortisol-reducing agents, it does not suppress the stress response entirely but rather buffers excessive reactivity while preserving the adaptive stress response needed for survival challenges.
Clinical Evidence
Telomere Length RCT
The landmark clinical study by Harley et al. (2011, Rejuvenation Research, n=117, PMID 20822369) is the most direct human evidence for dietary telomerase activation. Participants received cycloastragenol or placebo for one year. The primary endpoint was the change in the distribution of short telomere lengths in CD4+ and CD8+ T-lymphocytes measured by flow-FISH. The treatment group showed a significant increase in the proportion of long telomeres, with a corresponding shift in telomere length distribution. Immune function markers including naive T-cell counts and CD28 expression also shifted toward younger immune profiles. This study, while single-center and using a proprietary product, established proof-of-concept for telomerase activation by dietary compounds in humans.
Cancer Treatment Support
The most clinically robust evidence base for astragalus is in cancer supportive care. McCulloch et al. (2006, Journal of Clinical Oncology, PMID 16782926) conducted a systematic review and meta-analysis of 34 RCTs (n=2,815) finding that astragalus-based Chinese medicine formulations combined with platinum-based chemotherapy significantly improved one-year survival odds (odds ratio 2.82, 95% CI 1.67 to 4.76), tumor response rates, and quality of life scores in non-small cell lung cancer patients. While these trials used compound formulas, astragalus was the primary component in all trials. The mechanism is primarily immunostimulatory: preserving NK cell activity, T-lymphocyte counts, and interferon production against chemotherapy-induced suppression.
Immune Function in Healthy Adults
Multiple smaller RCTs have evaluated astragalus for immune function in healthy adults. Increased NK cell counts, improved vaccine antibody titers, and reduced upper respiratory infection incidence have been reported. Chen et al. (2014, American Journal of Chinese Medicine, PMID 24245567) found that astragalus supplementation reduced influenza susceptibility in healthy adults during influenza season, with parallel increases in NK cell activity and serum interferon levels, supporting the TLR4-mediated innate immune mechanism.
Kidney Disease
The application in nephroprotection has the most consistent RCT evidence outside oncology. A 2014 systematic review of 20 RCTs in diabetic nephropathy found significant reductions in 24-hour urinary protein excretion and stabilization of GFR in astragalus-treated patients compared to standard care alone. These effects are attributed to TGF-beta inhibition (anti-fibrotic), NF-kappaB-mediated inflammation reduction, and antioxidant protection of tubular cells.
Dosing Guidance
For general immune support and adaptogenic use, standardized astragalus root extract 400 to 800 mg per day (standardized to 0.5 percent astragaloside IV and/or 70 percent polysaccharides) is the typical evidence-supported range. For telomere-focused applications, cycloastragenol products at 5 to 100 mg per day provide higher concentrations of the specific telomerase-activating compound, though at significantly greater cost. Cancer treatment support trials have used 1,000 to 1,200 mg per day; this range should be implemented under oncology supervision. Benefits in immune function require 4 to 8 weeks of consistent use before clinical measurements change.
Getting the Most from Astragalus Extract
Choose a standardized extract (not raw herb powder): look for products standardized to 0.5 percent astragaloside IV or 70 percent polysaccharides for consistent bioactive content
For telomere-focused applications, cycloastragenol products (TA-65 or generic cycloastragenol extracts) provide higher concentrations of the specific aglycone responsible for hTERT upregulation; these are significantly more expensive than standard astragalus extract
Immune benefits are best observed with consistent daily supplementation for at least 4 to 8 weeks; seasonal use (autumn and winter) for respiratory infection prevention is a practical approach consistent with TCM tradition
Avoid during active flares of autoimmune conditions; immunostimulatory activity is beneficial for healthy immune function but potentially harmful in autoimmunity
Do not combine with immunosuppressant medications (cyclosporine, tacrolimus, mycophenolate, high-dose corticosteroids) without specialist consultation
For cancer patients using astragalus as an adjunct to chemotherapy, communicate use to your oncologist; the clinical evidence supports benefit but drug interaction monitoring is appropriate
Traditional TCM dosing uses 9 to 30 g per day of dried root in decoction, which extracts both saponin and polysaccharide fractions; modern standardized extracts at 400 to 1,200 mg per day are more convenient but dose equivalence to decoction varies by extraction method
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
First RCT (n=117) demonstrating that cycloastragenol supplementation significantly increased the proportion of long telomeres in CD4+ and CD8+ T-lymphocytes over one year, representing the first human evidence for dietary telomerase activation and telomere maintenance.
Demonstrated astragalus extract antiviral activity in viral myocarditis through NK cell activation and interferon induction, supporting the immunostimulatory mechanism in infectious disease contexts.
Meta-analysis of 34 RCTs (n=2,815) finding that astragalus-based treatments combined with platinum chemotherapy improved one-year survival by 33 percent and tumor response rates by 35 percent in NSCLC patients, representing the largest clinical evidence base for astragalus.
RCT demonstrating that APS injection reduced chemotherapy-induced immunosuppression markers, improved NK cell counts, and reduced infection rates in lung cancer patients, demonstrating immunoprotective mechanism in clinical oncology.
Comprehensive review contextualizing cycloastragenol telomerase activation within the biology of cellular senescence and aging, explaining the POT1-shelterin regulatory context and the plausibility of telomere maintenance strategies for healthy aging.
Mechanistic study confirming cycloastragenol increases hTERT mRNA and telomerase activity in human T-lymphocytes, with dose-dependent effects and specificity for hTERT upregulation over other telomerase complex components.
RCT demonstrating that astragalus supplementation reduced influenza susceptibility and duration in healthy adults, with significant increases in NK cell activity and interferon production, supporting immunostimulatory prophylactic benefit.
Comprehensive pharmacological review covering antioxidant, immunomodulatory, anti-inflammatory, and adaptogenic mechanisms, providing an integrated view of astragalus multi-target activity relevant to both TCM and modern supplement applications.